Schlafen family member 11 (SLFN11) DNA/RNA helicase has been identified as a biomarker that when upregulated in SCLC, correlates with increased cancer destruction when PARP inhibitor therapy is introduced [112]. This evidence concerns the gene SLFN11 and small cell lung carcinoma.